# US 2024/0191290 A1 · Methods for detection and reduction of sample preparation-induced methylation artifacts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0191290 A1
- Document ID: US20240191290A1
- Status: Published application
- Kind: A1
- Application number: 18/357,022
- Filed: 2023-07-21
- Published: 2024-06-13
- Earliest claimed: 2022-07-21
- Assignees: Guardant Health, Inc.
- Applicants: Guardant Health, Inc.
- Inventors: Andrew KENNEDY; Annie M. DEMAREE
- Web page: https://patentgrep.com/patent/US20240191290A1

## CPC

- C12Q 1/6869: Methods for sequencing
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosure relates to improved sequencing reactions. Specifically, the disclosure provides methods which allow for the identification of regions of a DNA molecule that were synthesized during an end repair and/or A-tailing reaction. Sequence data deriving from such synthesized regions may not be representative of the corresponding region in the original DNA molecules, for example it may contain artifactual methylation statuses. Accordingly, the identification of these synthesized regions allows for such potentially artifactual data to be identified and filtered accordingly.

## Claims

### Claim 1

A method comprising:
(a) subjecting a DNA sample to end repair to generate end-repaired DNA, wherein the end repair is performed with deoxynucleotide triphosphates (dNTPs), wherein at least one type of dNTP comprises a modified base;
(b) performing a ligation reaction to ligate adapters to the end-repaired DNA to generate adapted DNA, wherein the ligation reaction also seals nicks present in the end-repaired DNA;
(c) subjecting the adapted DNA to modification-sensitive sequencing to obtain sequencing data derived from the DNA sample, wherein the modification-sensitive sequencing is capable of identifying the base modification in the at least one type of dNTP; and
(d) analyzing the sequence data obtained in step (c) to identify one or more regions of the end-repaired DNA that were synthesized during the end repair by the presence of the base modification in the at least one type of dNTP used in step (a).

### Claim 2 (depends on 1)

The method of claim 1, (i) wherein the end repair is performed with a DNA polymerase which does not have 5′-3′ exonuclease activity and/or is not a strand displacing DNA polymerase, optionally wherein the DNA polymerase is T4 DNA polymerase, T7 DNA polymerase or Klenow fragment, or (ii) wherein the end repair is performed with a DNA polymerase which has 5′-3′ exonuclease activity and/or is a strand displacing DNA polymerase.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one type of dNTP which comprises a modified base modified base includes a dNTP comprising 4-methylcytosine (4mC), a dNTP comprising 5-methylcytosine (5mC), a dNTP comprising 5-hydroxymethyl-cytosine (5hmC), a dNTP comprising N6-methyladenosine (6 mA), a dNTP comprising bromodeoxyuridine (BrdU) and/or a dNTP comprising 8-oxoguanine (8oxoG).

### Claim 6 (depends on 1)

The method of claim 1, further comprising between steps (a) and (b) performing an A-tailing reaction.

### Claim 7 (depends on 6)

The method of claim 6, wherein:
(i) the end-repair and the A-tailing reaction are performed in the same reaction mixture, optionally wherein the end-repair and the A-tailing reaction are performed a single tube and/or optionally wherein the end-repair and the A-tailing reaction are performed without an intervening clean-up step; or
(ii) the end-repair and the A-tailing reaction are performed as separate reactions, wherein a reaction clean-up step is performed after the end-repair and before the A-tailing reaction, optionally wherein the reaction clean-up step removes unincorporated dNTPs.

### Claim 8 (depends on 7)

The method of claim 7, wherein:
(i) the A-tailing is performed using a DNA polymerase that does not possess 5′-3′ exonuclease activity and/or is not a strand displacing DNA polymerase, optionally wherein the DNA polymerase is HemoKlen Taq;
(ii) the A-tailing is performed using a thermostable DNA polymerase; or
(iii) the A-tailing is performed using Tag DNA polymerase, Tfl DNA Polymerase, Bst DNA Polymerase, Large Fragment or Tth DNA polymerase.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 7)

The method of claim 7, wherein:
(i) the A-tailing is performed using a DNA polymerase that does not possess 3′-5′ exonuclease activity, optionally wherein the DNA polymerase is Klenow Fragment lacking 3′-5′ exonuclease activity;
(ii) the A-tailing is performed using a DNA polymerase that possesses 5′-3′ exonuclease activity and/or is a strand displacing DNA polymerase: or
(iii) the A tailing reaction is performed at a higher temperature than the end repair, optionally wherein the end repair is performed at about 15-35° C. and/or the A tailing is performed at a temperature over about 60° C., further optionally wherein the temperature over 60° C. is about 60° C.-75° C.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the ligation reaction is a blunt-end ligation reaction or between steps (a) and (b) performing an A-tailing reaction and wherein the ligation reaction is a sticky-end ligation reaction.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the modification-sensitive sequencing comprises a conversion procedure that changes the base pairing specificity of the base or does not change the base pairing specificity of the base, depending on the modification status of the base.

### Claim 19 (depends on 18)

The method of claim 18, (i) wherein the modified base is a methylated cytosine and wherein the conversion procedure converts methylated cytosines, wherein the conversion procedure is Tet-assisted conversion with a substituted borane reducing agent, optionally wherein the substituted borane reducing agent is 2-picoline borane, borane pyridine, tert-butylamine borane, or ammonia borane or (ii) wherein the modified base is a methylated cytosine and wherein the conversion procedure converts unmethylated cytosines, wherein the conversion procedure is bisulfite conversion, oxidative bisulfite (Ox-BS) conversion, Tet-assisted bisulfite (TAB) conversion, APOBEC-coupled epigenetic (ACE) conversion, enzymatic methyl-seq (EM-seq) or single-enzyme 5-methylctyosine sequencing (SEM-seq) method.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the modification-sensitive sequencing comprises (i) nanopore-based sequencing, optionally wherein the at least one type of dNTP which comprises a modified base includes a dNTP comprising 4mC, a dNTP comprising 5mC, a dNTP comprising 5hmC, a dNTP comprising 6 mA, a dNTP comprising BrdU, dUTP, a dNTP comprising FldU, a dNTP comprising IdU, and/or a dNTP comprising EdU or (ii) single-molecule real time (SMRT) sequencing, optionally wherein the at least one type of dNTP which comprises a modified base includes a dNTP comprising a 4mC, a dNTP comprising 5mC, a dNTP comprising 5hmC, a dNTP comprising 6 mA, and/or a dNTP comprising 8oxoG.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the modified base is 5mC or 5hmC.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein analyzing the sequence data obtained in step (c) comprises the identification of regions comprising the modified base in non-CpG sequence contexts and classifying these regions as regions that were synthesized during the end repair or analyzing at least some of the sequence data corresponding to regions that are not identified as being synthesized during the end repair to detect the presence or absence of base modifications or mutations present in the DNA sample.

### Claim 27 (depends on 1)

The method of claim 1, wherein the modified base is other than 5mC or 5hmC, and a region of the one or more regions is defined as:
(i) the sequence between two non-modified bases spanning a modified base, wherein the bases are of the same identity to the modified bases present in the at least one type of dNTP; and/or
(ii) the sequence between a non-modified base and the end of a sequence read, wherein there is no additional non-modified bases between the non-modified base and the end of the sequence read, where the non-modified bases are the same identity as the modified base present in the at least one type of dNTP; or
wherein the modified base is a methylated cytosine, such as 5mC or 5hmC, a region of the one or more regions is defined as:
(i) the sequence between two non-methylated cytosines which span a methylated non-CpG cytosine; and/or
(ii) the sequence between a non-methylated cytosine and the end of a sequence read wherein there is no additional non-methylated cytosine between the non-methylated cytosine and the end of the sequence read.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The method of claim 1, further comprising: (i) filtering out sequence data from the one or more regions identified as being synthesized during the end repair such that these sequence data are not used for subsequent analysis; or (ii) flagging sequence data from the one or more regions identified as being synthesized during the end repair as potentially containing artifactual sequence data that may not be representative of the DNA sample.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The method of claim 1, wherein:
(i) the method is for detecting the methylation status of cytosines in the DNA sample, and wherein the analyzing the sequence data comprises filtering out the one or more regions of the end-repaired DNA that are identified as being synthesized during the end repair such that the one or more regions are not used to determine the methylation status of cytosines in the DNA sample; or
(ii) the method is for detecting the single nucleotide variants (SNVs) in the DNA sample, and wherein the analyzing the sequence data comprises classifying all base calls within the one or more regions as not having double stranded support.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the method further comprises quantifying the DNA damage in the DNA sample through the identification of the one or more regions of the end-repaired DNA that were synthesized during the end repair, optionally wherein the level of DNA damage is used to predict whether or not a portion of the DNA in the DNA sample is derived from cancerous cells.

### Claim 34

(canceled)

### Claim 35 (depends on 1)

The method of claim 1, wherein the DNA sample comprises cell-free DNA (cfDNA) and the method further comprises analyzing the sequence data obtained in step (c) to determine a level of measured artifacts in the cfDNA, and optionally (i) predicting whether or not a portion of the cfDNA is derived from cancerous cells using the level of measured artifacts and/or the comparison of the level of measured artifacts to one or more reference levels or (ii) determining a likelihood that a portion of the cfDNA is derived from cancerous cells using the level of measured artifacts and/or the comparison of the level of measured artifacts to one or more reference levels.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the DNA sample comprises cell-free DNA or DNA from formalin fixed paraffin embedded samples.

### Claim at position 39

-48. (canceled)

### Claim 49

A kit comprising:
a) a first reagent for end repair to generate end-repaired DNA, wherein the first reagent comprises at least one type of dNTP that comprises a modified base;
b) a second reagent for ligating adapters to the end-repaired DNA to generate adapted DNA, wherein the second reagent also seals nicks present in the end-repaired DNA;
c) a reagent for modification-sensitive sequencing that is capable of identifying the base modification in the at least one type of dNTP and/or a DNA polymerase for incorporating the first reagent into DNA during end repair; and
d) library adaptors having distinct molecular barcodes.

### Claim at position 41

-63. (canceled)
